Receptor protein tyrosine phosphatases are novel components of a polycystin complex  by Boucher, Catherine A. et al.
Biochimica et Biophysica Acta 1812 (2011) 1225–1238
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbadisReceptor protein tyrosine phosphatases are novel components of a
polycystin complex☆,☆☆
Catherine A. Boucher a,1, Heather H. Ward c,1, Ruth L. Case a, Katie S. Thurston a, Xiaohong Li b,
Andrew Needham a, Elsa Romero c, Deborah Hyink b, Seema Qamar a, Tamara Roitbak c, Samantha Powell a,
Christopher Ward d, Patricia D. Wilson b,2, Angela Wandinger-Ness c,⁎⁎, Richard N. Sandford a,⁎
a Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 2XY, UK
b Division of Nephrology, Mount Sinai School of Medicine, New York, NY 10029
c Department of Pathology, University of New Mexico HSC, Albuquerque, NM 87131, USA
d Mayo Clinic, Rochester, MN 55905, USAAbbreviations: ADPKD, autosomal dominant poly
activator protein 1; CPC-1, C-terminus of polycys
polycystin-2; LAR, leukocyte common antigen rela
collecting duct cell line; IB, immunoblot; IP, immuno
antibody; mCCD, cortical collecting duct cell line; MDCK
cell line; LRR, leucine rich repeat; NFCT, normal fetal co
normal human collecting tubule cell line; OG, octylgluco
PKD, polycystic kidney disease; RCTEC, renal cortical tu
receptor protein tyrosine phosphatase; TX, Triton-X 100
☆ Manuscript was handled by Executive Editor Ronal
☆☆ This article is part of a Special Issue entitled: Poly
⁎ Correspondence to: R.N. Sandford, Academic Dep
Addenbrookes Treatment Centre, Addenbrooke's Hosp
Tel.: +44 1223 762616; fax: +44 1223 217054.
⁎⁎ Correspondence to: A. Wandinger-Ness, Departme
New Mexico HSC, Albuquerque, NM 87131, USA.
E-mail address: rns13@cam.ac.uk (R.N. Sandford).
1 Authors contributed equally to the work.
2 Current Address: Centre for Nephrology, Universit
Hampstead Campus, London NW3 2PF, UK.
0925-4439/$ – see front matter © 2010 Elsevier B.V. Al
doi:10.1016/j.bbadis.2010.11.006a b s t r a c ta r t i c l e i n f oArticle history:
Received 2 August 2010
Received in revised form 16 November 2010
Accepted 19 November 2010
Available online 29 November 2010
Keywords:
Polycystins
Tyrosine kinase
Tyrosine phosphatase
Adherens junctions
Primary cilium
G-protein coupled signalingAutosomal dominant polycystic kidney disease (ADPKD) is caused by mutation of PKD1 and PKD2 that encode
polycystin-1 and polycystin-2. Polycystin-1 is tyrosine phosphorylated and modulates multiple signaling
pathways including AP-1, and the identity of the phosphatases regulating polycystin-1 are previously
uncharacterized. Here we identify members of the LAR protein tyrosine phosphatase (RPTP) superfamily as
members of the polycystin-1complex mediated through extra- and intracellular interactions. The ﬁrst
extracellular PKD1 domain of polycystin-1 interacts with the ﬁrst Ig domain of RPTPσ, while the polycystin-1
C-terminus of polycystin-1 interacts with the regulatory D2 phosphatase domain of RPTPγ. Additional homo-
and heterotypic interactions between RPTPs recruit RPTPδ. The multimeric polycystin protein complex is
found localised in cilia. RPTPσ and RPTPδ are also part of a polycystin-1/E-cadherin complex known to be
important for early events in adherens junction stabilisation. The interaction between polycystin-1 and RPTPγ
is disrupted in ADPKD cells, while RPTPσ and RPTPδ remain closely associated with E-cadherin, largely in an
intracellular location. The polycystin-1 C-terminus is an in vitro substrate of RPTPγ, which dephosphorylates
the c-Src phosphorylated Y4237 residue and activates AP1-mediated transcription. The data identify RPTPs as
novel interacting partners of the polycystins both in cilia and at adhesion complexes and demonstrate RPTPγ
phosphatase activity is central to the molecular mechanisms governing polycystin-dependent signaling. This
article is part of a Special Issue entitled: Polycystic Kidney Disease.cystic kidney disease; AP-1,
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Autosomal dominant polycystic kidney disease is a common hered-
itary disorder caused by mutation of the PKD1 or PKD2 genes [1–4]. The
ensuing disease is characterized by the proliferation of renal tubular
epithelia to form ﬂuid-ﬁlled cysts and in the long-term results in kidney
failure. The polycystin proteins (polycystin-1 and polycystin-2) encoded
by the PKD genes have regulatory functions in cell–cell adhesion, ciliary
calcium signaling, transcription and cell differentiation [5–10].
Polycystin-1 is a large cell surface, multi-membrane spanning
glycoprotein and is regulated through tyrosine phosphorylation [11–13].
Polycystin-1 is comprised of a novel array of evolutionary conserved
protein domains that form potential interaction sites for multiple
extracellular and intracellular ligands and are speculated to be
important for adhesion and signaling [11,14]. The 218 amino acid
cytoplasmic C-terminus contains a coiled-coil domain for interaction
with polycystin-2 and is modiﬁed by tyrosine phosphorylation
[12,13,15,16]. Nearly 50% of the extracellular region of polycystin-1 is
constituted of 16 copies of the PKD domain. The ﬁrst PKD domain is the
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been shown to have unique structural and biophysical properties
compatiblewith a role inmechanotransduction [17,18]. The polycystin-
1 ectodomain is also multiply glycosylated [11,19]. Polycystin-1 is
widely expressed during development and in adult tissues with
expression seen in kidney, liver, pancreas, vascular, skeletal and other
epithelial-derived tissues [20,21]. In renal epithelia, polycystin-1
localises to intracellular membranes, as well as to specialized plasma
membrane domains (including lamellipodia of spreading cells, cell–
matrix and cell–cell adhesion complexes, and the primary cilium) in a
spatially and temporally regulated manner [22–24]. A better under-
standing of polycystin-1 function depends on elucidating its extracel-
lular ligands and establishing how phosphorylation may regulate its
dynamic subcellular localisation and signaling.
Polycystin-1 forms a heteromeric complex with polycystin-2, a
cilial mechanosensitive cation channel that is activated by ﬂuid ﬂow
in vitro [5,25,26]. Polycystin-2 (TRPP2) is related to a large family of
channel proteins, mutations in which are closely associated with
kidney disease [27]. Flow responses can be blocked by antibodies to
the ﬁrst extracellular PKD domain of polycystin-1 identifying an
important role for this domain and the extracellular region of
polycystin-1 in mechanotransduction [5]. Coiled-coil domains within
the cytoplasmic C-terminal sequences of both polycystins play an
important role in the interaction of the two polycystins, but not in
ciliary localisation [6,15]. As yet, the connections between ﬂow-
induced channel activation and intracellular signaling remain to be
fully elucidated.
Together the polycystins interactwith ciliary proteins, focal adhesion
proteins, E-cadherin and desmosomal proteins [12,16,23,28–31]. These
interactions are continuously remodelled as a function of cellular
differentiation andmodiﬁed by both calcium concentration and tyrosine
phosphorylation [12,13,32,33]. Both polycystins are tyrosine phosphor-
ylated, most likely through the actions of c-Src and EGFR [12,13,34,35].
EGFR-dependent phosphorylation is in keeping with the critical role of
the EGFR signaling axis in the development and progression of both
ARPKD and ADPKD [36–40]. In vitro, the tyrosine phosphorylation of
polycystin-1 regulates G-proteins and several different signal transduc-
tion pathways including activator protein-1 (AP-1), calcineurin/NFAT,
phosphatidylinositol 3-kinase/Akt and mTOR [8,13,41–43]. AP-1 and
mTOR are dysregulated in ADPKD tissues [7,43,44] and the mTOR
inhibitor, rapamycin, is beneﬁcial in ameliorating disease progression in
animal models of PKD [45,46]. Polycystin-2 calcium channel function is
principally regulated through ser/thr phosphorylation [47,48], though
interactionwith regulators of channel activity (Kim1andEGFR) depends
on tyrosine phosphorylation [35,49,50]. Thus, tyrosine phosphorylation
plays important roles in the regulation of the polycystins.
Tyrosine phosphorylation is normally continuously turned over
through the action of speciﬁc phosphatases to terminate signaling and
allow dynamic regulation of interactions. In ADPKD, primary patient
derived PKD cells exhibit increased polycystin-1 phosphorylation [29].
Excessive tyrosine kinase activationhas alsobeen linked to cyst formation
inADPKDby triggeringhyperproliferation, apoptosis, disruptionof planar
cell polarity and aberrant ﬂuid secretion [38–40,51–53]. Abnormal
composition and localisation of cell adhesion complexes, adherens
junctions and desmosomes, and altered phosphorylation of polycystin-
1 are also a feature of cystic epithelial cells suggesting that defects in
phosphorylation may be inextricably linked to the changes in cell
adhesion and ciliary signaling that contribute to the development of renal
cysts in this disease [23,29]. Although phosphatase activity has been
found associated with the polycystins [29,34], the identity of the
phosphatase(s) remains to be identiﬁed.
Here we identify members of the classical receptor protein tyrosine
phosphatase (RPTP) family as regulatory, interacting partners of a
multimeric polycystin protein complex. RPTPs are modular proteins
containing variable extracellular domains, a single transmembrane
domain and two intracellular protein tyrosine phosphatase (PTP)domains [54,55]. Substrate speciﬁcity and functional diversity of the
RPTPs is achieved by alternative splicing, proteolytic cleavage and the
formation of large homo- and hetero-multimeric complexes [55–57].
The ﬁrst membrane proximal PTP domains (D1) are catalytically active
whilst the second structurally identical membrane distal PTP domains
(D2), have little or no activity but are proposed to have a regulatory role
[58]. Co-immunoprecipitations and substrate-trapping mutants have
been used to demonstrate interaction of RPTPs with interacting
partners, such as the cadherins and focal adhesion proteins which are
also partners of the polycystins [12,16,29,34,59–62]. We show that the
ﬁrst extracellular PKD domain of polycystin-1 interacts with the ﬁrst
extracellular Ig domain of RPTPσ (E-subunit), a member of the LAR
family of RPTPs, whilst the intracellular cytoplasmic tail of polycystin-1
interacts with the intracellular phosphatase domains (P-subunit) of
RPTPγ. RPTPγ is shown to dephosphorylate a c-Src phosphorylated
residue, Y4237, in the C-terminus of polycystin-1. This residue, together
with Y4127 is able to regulate AP-1 signaling. The combined data
suggest that RPTPs and tyrosine phosphorylation, play a central role in
modulating the mechanical and signaling functions of the polycystin
complex.
2. Materials and methods
2.1. Cloning and expression
The following reference sequences were used: PKD1 (nm_000296),
PKD2 (nm_000297), PTPRS (nm_002850), PTPRG (nm_002841) and
PTPRD (nm_002839). The ﬁrst PKD domain of human polycystin-1
(residues 268–356)was expressed and puriﬁed as previously described
[17]. Speciﬁc RPTP domains were ampliﬁed by PCR from human fetal
kidney marathon-ready cDNA (Clontech) and veriﬁed by direct
sequencing. RPTPγ D1 (Ile828–Asn1130), substrate-trapping RPTPγ
D1with Asp1028Ala mutation, and RPTPσ D1 (Ile1373–Arg1659) were
cloned into pET30a in frame with the N-terminal His-tag. Site directed
mutagenesis was carried out using the Quikchange® kit (Stratagene).
The CD44-CTD expression construct consisting of the extracellular
and transmembranedomains of CD44 (Met1–Ser291) in-framewith the
C-terminus of polycystin-1 (Leu4105–Thr4302) was cloned into
pcDNA3.1 (Clontech).
2.2. Peptide “phage display”
A Ph.D.-7™ “phage” display random peptide library (New England
Biolabs) was screened to identify short peptide sequences that bound to
PKD domain 1 according to the manufacturer's protocol. Folding of PKD
domain1was conﬁrmedusing circular dichroismandNMRspectroscopy.
After three rounds of biopanning 26 independent “phage”plaques and an
aliquot of the eluted pool of “phage”were sequenced. Peptide sequences
were searched against public protein databases using BLAST (http://
www.ncbi.nih.gov/BLAST/) and PEPSEARCH (http://www.sanger.ac.uk/
Users/agb/Pepsearch/). An enzyme-linked immuno-sorbant assay
(ELISA) was used to conﬁrm binding between PKD domain 1 and
individual “phage” clones. Additional “phage” clones expressing protein
speciﬁc peptide sequences were generated using the Ph.D.-7 peptide
display cloning system according to the manufacturer's instructions.
2.3. Structural modelling
A structural model of the ﬁrst Ig domain of mouse RPTPσ (residues
31–130) was generated using Phyre, a successor to 3D-PSSM.
Yeast-2-hybrid assays. The CytoTrap® 2-hybrid system (Stratagene)
was used to screen for proteins that interact with the C-terminus of
polycystin-1 (CPC-1). CPC-1 (Leu4105–Thr4302) expressed in pSOS
was used to screen 1.2×106 clones of a testis pMyr cDNA library (using
the manufacturer's protocol).
1227C.A. Boucher et al. / Biochimica et Biophysica Acta 1812 (2011) 1225–1238Potential interactions between the polycystin-1 and polycystin-2
C-termini and the RPTP PTP domains were investigated by yeast 2-
hybrid mating assays using CytoTrap® and Matchmaker™ standard
protocols. RPTPσ D1 (Ala1376–Val1656), substrate-trapping RPTPσ
D1 with Asp1557Ala mutation, RPTPσ D2 (Arg1659–Ala1947), RPTPγ
D1 (Lys831–Val1127), substrate-trapping RPTPγ D1 with Asp1028Ala
mutation, RPTPγ D2 (Asn1130–Asn1418) and RPTPδD2 (Ser1654–
Thr1912) were used. The C-terminus of polycystin-2 (CPC-2)
(Asp690–Val968) was also used. For the Matchmaker™ system,
high stringency interactions were detected by growth on SD glucose/-
Ade/-His/-Leu/-Trp/X-α-gal plates and medium stringency interac-
tions were detected by growth on SD glucose/-His/-Leu/-Trp plates.2.4. Antibodies
The following primary antibodies against the RPTPswere used: anti-
PTPσ (C19), anti-PTPγ (C18), anti-PTPγ (M18) and anti-LAR (7/LAR
mouse mAb IgG2a raised against aa 24–196 BD-Biosciences), and
monoclonal anti-PTPσ (17G7.2) [63]. A new rabbit polyclonal anti-
RPTPσ (KTPTPσ) was raised and afﬁnity puriﬁed against peptide
sequence NH2-Cys-KPDADGFIMVYLPDGQ -CONH2. A new rabbit poly-
clonal anti-RPTPδ (KTPTPδ) was raised and afﬁnity puriﬁed against
peptide sequence NH2-Cys-GKFIKPWESPDEMEL-CONH2. A new rabbit
polyclonal anti-RPTPγ (CBPTPγ) was raised and afﬁnity puriﬁed against
peptide sequence NH2-Cys-STKENGNGPMTVDKN-CONH2. Supplemen-
tary Fig. 1 shows locations of peptides within RPTP sequences and
immunoblots for newly prepared antibodies±peptide blocking.
The following antibodies against the polycystins were used: rabbit
polyclonal anti-polycystin-2 PKD2-CFP [64], mouse monoclonal anti-
polycystin-1 (7e12) [65], rabbit polyclonal anti-polycystin-1 (PWPC-1)
[16], rabbit polyclonal anti-polycystin-1 (NM005) [6,29]. Rabbit
polyclonal anti-polycystin-1 (LRR) was raised against LRR residues
27–360 and rabbit polyclonal anti-polycystin-1 PKDdomain-1 (Dom-1)
was raised against residues 268–356 using standard immunization
protocols. Antiserum was puriﬁed using protein-A Sepharose and the
speciﬁcity of the antibody conﬁrmed by ELISA, western blotting and
immunocytochemistry with and without preadsorbtion with the
immunizing protein (data not shown).
Other primary antibodies were: anti-acetylated α-tubulin (Sigma),
mouse monoclonal anti-CD44 (E1/2) [66], rabbit polyclonal anti-GFP
(Ab6556; AbCam), mouse monoclonal anti E-cadherin (Transduction
Laboratories), rabbit polyclonal anti-E-cadherin (Santa Cruz SC-7870),
normal rabbit IgG (Santa Cruz SC-2027) mouse monoclonal anti pan-
cadherin (Sigma), mouse monoclonal anti-actin (MP Biomedical,
Aurora, OH).
The following secondary antibodies for immunoﬂuorescence were
obtained fromMolecular Probes: Alexa Fluor® 488 donkey anti-rabbit
IgG, Alexa Fluor® 555 donkey anti-rabbit IgG, Alexa Fluor® 488
donkey anti-mouse IgG, Alexa Fluor®, Alexa Fluor® 555 donkey anti-
mouse IgG, 488 donkey anti-goat IgG and Alexa Fluor® 546 donkey
anti-goat IgG.2.5. Cell lines and reagents
HeLa, HEK293, MDCK, A431, mCCD and IMCD cells were main-
tained in DMEM supplemented with 10% fetal calf serum, 2mM
glutamine, 10g/L streptomycin and penicillin. NHCT and NFCT cells
have been previously described [13]. Normal primary human kidney
and primary human ADPKD cells were isolated and cultured as
described [29]. Immortalized human wild-type (wt) renal cortical
tubular epithelial cells (RCTEC) and PKD9–12 cells were cultured as
described [67,68]. PKD9–12 cells are homozygous for a truncating
mutation in PKD1, Q2556X. Tissue and cell lysates were prepared
according to standard protocols.2.6. Immunoprecipitation and immunoblot analyses
Polycystin-1 and E-cadherin immunoprecipitation and immuno-
blotting were performed as previously described with attention to the
following details [16,29,69]. For immunoprecipitation and immuno-
blot experiments using immortalized (RCTEC) or primary normal
kidney and ADPKD cells, cells were plated on 100 mm culture dishes
and grown to conﬂuence. Cell lysates were prepared by washing with
PBS buffer to remove growthmedium and addition of 1ml Lysis Buffer
(150 mM NaCl, 10 mM Tris–HCl, pH 7.4, containing 1% (vol/vol) TX-
100 and a protease inhibitor cocktail) or 1 ml OG Lysis Buffer (150mM
NaCl, 10 mM Tris–HCl, pH 7.4, containing 1% (wt/vol) n-octylgluco-
side (BD) and a protease inhibitor cocktail CLAP). Lysates were
clariﬁed by high-speed centrifugation and an aliquot of the total cell
lysates was reserved for direct immunoblot analysis. Actin was used
to conﬁrm equal protein concentrations in cell lysates. Several
measures were used to assess the speciﬁcity of the observed protein
interactions: IgG isotype control immunoprecipitations were negative
for the polycystin and E-cadherin complexes, membrane proteins
associated with endosomes and cytoskeletal proteins were absent
from immunoprecipitates, and similar results were obtained using
two different detergents. Because ADPKD cells express variable levels
of E-cadherin and some N-cadherin ([29,69] and Fig. 5), immunopre-
cipitations were repeated at least 4 times for both detergents using
monoclonal or polyclonal antibodies directed against E-cadherin, a
monoclonal antibody directed against N-cadherin or a monoclonal
pan-cadherin antibody to assure consistency of results. Immunopre-
cipitates were collected using protein G-Sepharose, resolved on 4–
15% SDS-PAGE gradient gels and transferred to nitrocellulose. Blots
were probed for RPTPσ (C19), RPTPδ (KTPTPδ), polycystin-1 (NM005)
or E-cadherin (pAb or mAb), N-cadherin (mAb) or pan-cadherin
(mAb).
2.7. Confocal microscopy
Cells were grown on polycarbonate membranes (Transwells, Costar)
until conﬂuent. For cilia growth, IMCD cells were grown for 7 days. Cells
were then washed in PBS, ﬁxed 4% paraformaldehyde in PBS, permea-
bilized in 0.1% Triton-X 100 prior to incubationwith primary antibody for
1 h at room temperature. After washing with PBS, the cells were
incubated for 1 h with secondary antibody. After further washes in PBS
membranes were excised from the transwell and mounted onto slides
with vector shield DAPI mounting media (Vector Laboratories). Primary
normal kidney and ADPKD cells were grown to subconﬂuence on glass
coverslips,ﬁxed in3%paraformaldehyde, permeabilizedwith0.1%Triton-
X 100, stained andmounted inMowiol [23,29]. RCTEC and PKD9–12 cells
were grown on coverslips or 0.4 μm pore size 6-well Culture insert
(Falcon 353090). Cells were washed with PBS+ and pre-treated with
0.01% saponin in Pipes buffer, pH 6.8 (80 mM PIPES, 5 mM EGTA, 1 mM
MgCl2) for 5 min. Cells were subsequentlywashedwith PBS+, ﬁxed in 3%
PFA, quenchedwithNH4Cl in PBS+ and permeabilizedwith 0.1% Triton-X
100 in PBS+ for 5 min. Cells were blocked with 0.4% ﬁsh skin gelatin
in PBS+ and incubated 1 h with primary and secondary antibodies in
PBS+ containing 0.4% ﬁsh skin gelatin. Stained cells were mounted in
Mowiol. For the IMCD cells, A431 cells, and MDCK cells confocal
images were taken on a Zeiss LSM510 META confocal microscope
using 63× objective. Images were further processed using Adobe
Photoshop. For the HFCT cells microscopy was carried out on a Leica
TCS-SP laser scanning confocal microscope equipped with an Ar-UV
laser (350 nm), Argon laser (488 nm) and a diode laser (561 nm).
Step size between optical sections was determined by the Nyquist
limit. Stacks were volume rendered using Volocity software (Impro-
vision, Inc, Lexington, MA). Primary normal kidney and ADPKD cells
were imaged using a Zeiss LSM510 or a Zeiss META ﬁtted and a 63×
objective. For the RCTEC and PKD9–12 cells images were captured
using the BioRad Radiance 2100 Microscope (http://hsc.unm.edu/
Table 1
Proteins with sequence similarity to VASFHRQ identiﬁed using Pepsearch and BLAST.
No. Accession
no.
Protein name Gene
name
Predicted
localisation
Sequence
′phage display peptide
sequence
VASFHRQ
1 O43457 Hypothetical 9.2KDa
Protein
intracellular VASFHRC
2 O60536 Antigen NY-CO-43 intracellular VTSFHSQ
3 Q13136 Liprin-alpha 1 PPFIA1 intracellular VDSFHRN
4 Q96IY4 Carboxypeptidase B2
precursor
CPB2 intracellular VASFLRR
5 Q13332 Receptor-type tyrosine
protein phosphatase, S
PTPRS extracellular VASFVCQ
6 P10586 Receptor-type tyrosine
protein phosphatase, F
LAR extracellular VASFVCQ
7 P53708 Integrin Alpha-8 ITGA8 extracellular VVEFHRQ
8 Q8WZ42 Titin TTN intracellular VASFRIQ
9 O15535 Zinc Finger Protein 193 PRD51 intracellular VAHRHRQ
10 O75145 Liprin-alpha 3 PPFIA3 intracellular VDSFHRV
11 O75335 Liprin-alpha 4 PPFIA4 intracellular VDSFHRT
12 Q9ULV5 Heat Shock Transcription
Factor 4
HSF4 intracellular ASFVRQ
13 Q03164 Zinc ﬁnger protein HRX MLL intracellular ASKHRQ
14 O94874 KIAA0776 Protein KIAA0776 Nuclear VDSFFRQ
15 Q12913 Receptor-type tyrosine-
protein phosphatase eta
PTPRJ extracellular AESFHKQ
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stacks were acquired and volume renderings were generated using
Voxx, a PC-based image analysis program developed at the Indiana
Center for Biological Microscopy [70]. Volumes are depicted begin-
ning at the top of the nucleus through the basal membrane. Voxx is
available at no charge (http://nephrology.iupui.edu/imaging/voxx).
2.8. Kinase and phosphatase assays
Phosphatase activity was determined using pNPP as substrate [71].
Brieﬂy, varying amounts of recombinant RPTPσ D1, RPTPγ D1 and
LAR-D1 were assayed in a microtiter plate at 30°C in 150μl of buffer
(50 mM Tris, pH 6.8, 2 mM DTT) with 20 mM pNPP (Sigma).
Absorbance readings were taken at 405 nm after 10 and 20 min of
incubation. These values were used to calculate the relative unit
activity compared to puriﬁed LAR-D1 protein (Sigma).
The activity of the recombinant RPTP phosphatase D1 domains
against the C-terminus of polycystin-1 was measured as follows. CPC-
1 was tyrosine phosphorylated as previously described [13]. CPC-1
(residues 4105–4302) was expressed as a His-tagged fusion protein in
pET28a (Novagen). Protein was puriﬁed using Ni-NTA afﬁnity
chromatography and dialysed into 50 mM Tris (pH 7.4), 0.5% N-
laurylsarcosine. Based on a series of protein refolding experiments, N-
laurylsarcosine was found to be the best detergent for refolding CPC-1
following puriﬁcation. However, the detergent is not essential for
Src-dependent phosphorylation of polycystin-1 as it was not in-
cluded in the initial c-Src assays performed by [13]. Ten μg of fusion
protein was incubated at 37 °C for 30 min with 500 ng c-Src (150
units) in Kinase Buffer (10 mM HEPES, 2 mMMnCl2, pH 7.5) and 1 μl
[γ-32P]ATP (3000 Ci/mmol, Amersham) and subsequently heat
inactivated at 65 °C for 20 min (control reactions conﬁrmed that no
kinase activity could be detected following this treatment). Reaction
products were then incubated with 10 units of phosphatase domains
at 30 °C for 20 min in 10 mM imidazole, pH 7.0 containing 2 mM
EDTA, 5 mM DTT, 100 mM NaCl and resolved by 10% SDS-PAGE prior
to autoradiography.
2.9. AP-1 luciferase assay
Site-directed mutagenesis was used to generate Y4127F, Y4237F
and double mutant constructs of pMyr-EGFP-CTD [72]. Hek293 cells
were co-transfected with each pMyr-EGFP-CTD and 5xjun:ATF ﬁreﬂy
luciferase reporter construct by the CaCl2 precipitation method and
grown in serum-freemedium [7]. Cell lysates were collected 48 h after
transfection, and luciferase activities were determined using a
luminometer (Luciferase Reporter Assay; Promega). Comparisons
were made with pMyr-EGFP-CTD4147X co-transfected with the 5x-
jun reporter construct and a negative control transfected with the 5x-
jun reporter construct only. Cell lysates were Western blotted with
anti-GFP to conﬁrm expression of chimeric protein. Western blots
were scanned and the density of each band measured using ImageJ.
Means, standard deviations and Student t-tests were calculated using
Excel.
3. Results
3.1. The ﬁrst polycystin-1 PKD domain interacts with the RPTPσ Ig
domain
Based on its importance in regulating mechanotransduction, we
used the ﬁrst PKD domain of polycystin-1 to screen 2×1011
bacteriophage clones from a random 7-mer peptide bacteriophage
display library (New England Biolabs). The peptide library was used to
overcome potential biases in gene expression that may occur with the
use of tissue and temporal speciﬁc cDNA libraries. After three rounds
of biopanning a single peptide sequence, VASFHRQ, represented 73%of the total number of bacteriophage clones sequenced. Bacteriophage
clone sequences that matched known extracellular or membrane-
associated proteins included integrin α8, members of the leukocyte
common antigen related (LAR) family of receptor protein tyrosine
phosphatases (RPTPs) and the RPTP interacting liprin proteins, among
others (Table 1). The known association of polycystin-1with adhesion
molecules and its regulation through phosphorylation prompted us to
clone peptide sequences corresponding to integrin α8, RPTPσ, LAR
and RPTPδ into a bacteriophage display vector (M13KE gIII). Binding
was assessed by ELISA to determine which of the cloned sequences
with similarity to VASFHRQ bound speciﬁcally to the PKD domain 1
(Fig. 1A and B). Speciﬁc binding only occurredwith the original library
sequence, VASFHRQ (expressed with a GGGS spacer sequence that
was present in all bacteriophage clones), and a sequence that is
identical in RPTPσ and LAR, VASFVCQ. The VASFVCQ sequence
corresponds to amino acids 49–55 of RPTPσ and 39–45 of LAR.
These residues are predicted to form a β-strand in the ﬁrst
extracellular immunoglobulin (Ig) domain of RPTPσ and LAR based
on secondary structure predictions and structural modelling (Fig. 1C).
Somewhat surprisingly, PKD domain 1 did not directly interact with
the highly homologous VASFICQ sequence derived from RPTPδ.3.2. Polycystin cytoplasmic C-terminal domains of the polycystins
interact with RPTPγ
The cytoplasmic polycystin-1 C-terminus is reversibly tyrosine
phosphorylated and the modiﬁcation is demonstrated to regulate
interactions with proteins involved in cell adhesion [12,13,16,29,34].
Therefore, we also analyzed the interactions between the cytoplasmic
regions of the RPTPs and the polycystin-1 C-terminal domain using
two different yeast two-hybrid systems (CytoTrap® and Matchmak-
er™) (Fig. 1D–F). RPTPσ contains two phosphatase domains, D1 and
D2. The RPTP D1 domains are considered to be the active site domains,
while the D2 domains are regulatory in nature [55]. A strong
interaction was observed using the CytoTrap system between the C-
termini of polycystin-1 and polycystin-2, thereby conﬁrming the
sensitivity of the system for detecting known protein-protein
interactions (Fig. 1E). In addition, the Cytotrap screen identiﬁed
novel interactions between the intracellular RPTPγ D2 regulatory
Fig. 1. TheﬁrstPKDdomainofpolycystin-1binds speciﬁcally to apeptide sequence fromRPTPσ/LAR. (A)Bindingofwild-typePKDdomain1 tobacteriophagedisplay clonesexpressingprotein
speciﬁc peptide sequences. WT corresponds to wild type empty vector. Each column represents the mean and standard error of three separate experiments. (B) Protein speciﬁc peptide
sequencesused in thebacteriophagedisplay assay. (VAS=single peptide sequence represented in73%of the total numberof bacteriophage clones sequenced). (C) Structuralmodel of theﬁrst
Ig domain of RPTPσ generated using Phyre/3D-PSSM. The sequence VASFVCQ (orange) corresponds to a region containing the second β strand of an I type Ig domain (green). Residues are
represented in ball and stick. (D) Cartoon representation of RPTP isoforms and RPTP domains. Full-length RPTPs are proteolytically cleaved near the transmembrane domain by a furin-like
endoprotease to produce an extracellular domain (E-subunit) and tandem phosphatase domains (P-subunit), followed by calcium-dependent proteolytic cleavage to shed the extracellular
domain.Regionsmarked in red correlate to sequencesused forCytoTrapandMatchmaker assays that are listed in table belowcartoon. (E) Summaryof interactions betweenPTPdomains from
RPTPσ, RPTPδ and RPTPγ and the polycystins detected using the CytoTrap® yeast-2-hybrid system. The clones in the ﬁrst row are expressed in pMyr and clones in the ﬁrst column are
expressed in pSos. (F) Summary of Matchmaker™ yeast 2-hybrid results. The clones in the ﬁrst row are expressed in pGADT7 and the clones in the ﬁrst column in pGBKT7. Interactions are
indicated as●=strong interaction,●=weak interaction,○=no interaction. WT=wild-type, ST=substrate trapping, CPC-1=polycystin-1 C-terminus, CPC-2=polycystin-2 C-terminus.
Positive (+ve) and negative control interactions were carried out according to the manufacturer's protocol.
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between the RPTPγ D1 catalytic domain and the polycystin-2 C-
terminus. The RPTPγ D2/polycystin-1 interaction was conﬁrmed in
the Matchmaker system, though the RPTPγ D1/polycystin-2 was
undetectable in this system (Fig. 1F). The Matchmaker system also
enabled detection of several homo- and heterotypic interactions
between RPTP wild-type and substrate-trapping mutant subunits;
including homotypic interactions between RPTPσ D1 domains, andheterotypic interactions between RPTPσ D1/RPTPγ D2 and RPTPσ D1/
RPTPδ D2 (Fig. 1F). The observed homotypic RPTPσ D1 and RPTPσ D1/
RPTPδ D2 interactions agree with the published literature [58,73].
Therefore, the RPTPσ, RPTPδ, RPTPγ phosphatases are capable of
forming a heteromultimeric complexes with one another andwith the
polycystins, poising them to play regulatory roles in the function of
the polycystins (see graphical abstract and Fig. 7 for interaction
summary).
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cilia of renal tubular epithelial cell lines
The RPTPs have been best characterized in the brain and in neurons
[55]. Immunoblots using severalmAbandpAbdirected against individual
RPTPs demonstrated that RPTPσ, RPTPδ, RPTPγ, and LAR are also highly
expressed in kidney tissue extracts and cultured renal cell lysates, among
others (Supplementary Fig. 1). Likely due to the known furin and calcium
activated proteolytic cleavage of the RPTPs [55] (see Supplementary
Fig. 1A-cartoon), multiple bands were detected with most of the
antibodies (Supplementary Fig. 1B-J). Molecular weights were as
expected and peptide blocking experiments further conﬁrmed antibody
speciﬁcity. These RPTP antibodies were used for IP/Western assays to
conﬁrm the interaction between endogenous polycystin-1 and the LAR-
family RPTPs.
Immunoprecipitation of polycystin-1 (with antibody PWPC-1)
from immortalized normal human kidney and ADPKD cell lysates co-
precipitated RPTPσ, but not LAR (Fig. 2A). RPTPγ, which interacts with
polycystin-1 only via the cytoplasmic C-terminal sequences was only
co-precipitated from normal kidney cell lysates but not from ADPKD
cell lysates (Fig. 2A), and is consistent with frequent PKD1 mutations
that result in C-terminal truncation of polycystin-1 [52]. RPTPδ though
not a direct interacting partner of the polycystins (Fig. 1E–F) was also
co-precipitated with polycystin-1 (Fig. 2B), most likely through
known interactions between RPTPσ and RPTPγ (Fig. 1F and [58]).
Fig. 2B further demonstrates the speciﬁcity of the co-immunopreci-
pitations in that no irrelevant bands were detected over the length of
the blot and the speciﬁc bandswere absent when an irrelevant control
antibody was used for the immunoblot.
In fully polarized renal tubular epithelia, polycystin-1 is expressed
in primary cilia [30]. Using rat kidney inner medullary collecting duct
cell line (IMCD) cells, RPTPσ, RPTPγ and RPTPδ were all found co-
localised with acetylated tubulin, a ciliary marker, as well as with
polycystin-1 (Fig. 3A–B). The ciliary localisation of RPTPσ, RPTPδ andFig. 2. RPTPs form a complex with polycystin-1. Polycystin-1 was immunoprecipitated
(A) Immunoblot analyses of whole cell lysates from immortalized normal human ki
immunoprecipitates were performed to detect the presence of polycystin-1, RPTPσ, R
immunoprecipitated with PC1 antibody relative to the fraction of protein precipitated with
human fetal kidney (NFCT) cells for polycystin-1 and RPTPδ. Fold enrichment of RPTPδ in PC
IgG heavy chain in the immunoprecipitates. Proteins were detected with the following antib
RPTPδ (KTPTPδ), control panel A (isotype matched Ig), control panel B (irrelevant antibodyRPTPγ was further conﬁrmed by peptide blocking experiments and
through the use of two different antibodies for RPTPσ (KTPTPσ; C19
antibodies) and RPTPγ (C18; CBPTPγ antibodies) (Fig. 3C–D).
3.4. RPTPs co-localise with polycystin-1 and E-cadherin at the
basolateral membrane
Polycystin-1 functions in cell–cell adhesion, cell–matrix adhesion,
calcium channel regulation and signal transduction and is regulated
both temporally and spatially [24]. During the early phase of renal cell
polarization, polycystin-1 localises to focal adhesions [16], followed
by polycystin-1 presences at basolateral membrane junctions, such as
desmosomes [23,31] and adherens junctions, where polycystin-1 is
known to play a role in E-cadherin localisation to the adherens
junction [29,69,74]. Upon the formation of stable junctions, poly-
cystin-1 retreats from the lateral membrane [ 23] and is found in the
apical membrane and primary cilia [5,30,75]. LAR and RPTPσ also have
demonstrated roles in regulating cadherins and cell–cell adhesion, as
well as integrins and cell–matrix adhesion [62]. Like polycystin-1, the
RPTPs are also closely associated with tyrosine kinases such as EGFR
and src [13,32,34,55,59,76,77]. EGFR is also found in cilia where it
regulates polycystin-2 activity [35]. Based on the multitude of
interconnections, it was also of interest to analyze the co-localisation
of polycystin-1 and RPTPs with the lateral cell membrane and
adherens junctions marked by E-cadherin.
Analysis of IMCD cells stably expressing RPTPσ::GFP (corresponding
to a major RPTPσ isoform isolated from a kidney cDNA library, lacking
the FNIII domains 4–7) was exclusively localised to the lateral
membrane (Fig. 4A). Immunolabeling of endogenous RPTPσ also
showed RPTPσ at the lateral plasma membrane where it co-localised
with polycystin-1 and E-cadherin in conﬂuent, non-ciliated IMCD cells,
(Fig. 4B–C).
To test the functional signiﬁcance of the RPTP localisation
with E-cadherin at lateral membranes, their localisations werefrom cell lysates using a speciﬁc antibody, PWPC-1, directed against the CPC-1.
dney (NHCT) and ADPKD cells, control IgG immunoprecipitates and polycystin-1
PTPγ and LAR. Enrichment shown in graph was calculated as fraction of protein
control IgG. (B) Immunoblot analyses of whole cell lysates from immortalized normal
1 immunoprecipitates was 5-fold (calculated as described in panel A). Asterisk denotes
odies: polycystin-1 (PWPC-1), RPTPσ (17G7.2), LAR (BD Biosciences), RPTPγ (CBPTPγ),
against sprouty). N=4 for all panels.
Fig. 3. RPTPs localise to the primary cilia of renal epithelial cells with polycystin-1. (A) Confocal immunoﬂuorescence images show polycystin-1 (LRR mAb), RPTPσ (KTPTPσ pAb),
RPTPγ (C18 pAb) and RPTPδ (KTPTPδ pAb) co-localise with acetylated α-tubulin (Ac-Tub, mAb) in the primary cilium of IMCD cells. (B) Confocal immunoﬂuorescence images show
RPTPσ (KTPTPσ pAb), RPTPγ (C18 pAb) and RPTPδ (KTPTPδ pAb) co-localise with polycystin-1 (7e12 mAb or LRR mAb) in a single cilium. (C) Confocal immunoﬂuorescence images
show the speciﬁcity of the antibodies to RPTPγ (C18), RPTPσ (KTPTPσ) and RPTPδ (KTPTPδ) when blocked with their respective antigen raising peptides. In peptide-blocked
samples, only acetylated α-tubulin (Ac-Tub) staining of the primary cilium of IMCD cells was detected. (D) Confocal immunoﬂuorescence images show RPTPγ (CBPTPγ) and RPTPσ
(C19) co-localise in the primary cilium of HFCT cells. N≥3 for all panels.
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(using immortalized lines andprimary cells). BothRPTPσ andRPTPδ co-
localised with E-cadherin at the lateral membrane and intracellular
membranes of normal immortalized kidney cells (RCTEC) and were
exclusively intracellular in immortalized PKD9–12 cells (Fig. 4D–G),
as previously shown for E-cadherin [29,69]. In more conﬂuent,
polarized RCTEC and PKD9–12 cells, there was limited co-localisation
between E-cadherin and RPTPσ (Fig. 4E). Similar trends were observed
in primary cells (Fig. 4H). Filter-grown, polarized RCTEC cells revealed
that RPTPδ co-localised at the lateral membrane with E-cadherin of
normal cells. Renal epithelial PKD cells fail to trafﬁc E-cadherin to
adherens junctionsandexhibit signiﬁcantly less intracellular E-cadherin
compared to normal renal epithelial cells [34]. The lateral membranelocalisation of RPTPδwas lost in the PKD9–12cells,where the levels of E-
cadherin were also signiﬁcantly reduced, and RPTPδ and E-cadherin
were conﬁned to the intracellular compartment (Fig. 4F–G). In
subconﬂuent primary cells, RPTPδ was often seen at the leading edge
ofmembrane rufﬂes in spreadingnormal kidney cells, a pattern thatwas
not apparent in primary PKD cells where the staining was diffusely
localised across the cell membrane and in concentrated in the Golgi
region (Fig. 4I).
3.5. RPTPs interact with E-cadherin
In previous studies, we identiﬁed a multimeric complex between
the polycystins, E-cadherin and β-catenin that was disrupted in
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kinase and phosphatase activities and polycystin was increasingly
phosphorylated in ADPKD cells heterozygous for the Q2556X
mutation in PKD1. Therefore, co-immunoprecipitation experiments
were carried out using primary normal human kidney and ADPKD
cells to determine if RPTPs might represent the phosphatase activity
that is part of a polycystin/E-cadherin complex. We also wanted to
comparatively evaluate ADPKD related changes that would lend
functional signiﬁcance to any identiﬁed interactions. E-cadherin was
immunoprecipitated from three different normal (67F05, 59M04,
57M03) and three different ADPKD (51M06, 46M06, 46F04) patient
derived primary cells. The immunoprecipitates were subsequently
immunoblotted for E-cadherin, RPTPσ, RPTPδ and polycystin-1 (PC1)
(Fig. 5A). (NB: Since a polycystin-1:RPTPγ complex appeared to be
present only in the immortalized normal human kidney cells and not
the ADPKD cells (Fig. 2), it was not retested in the primary cell lines).
RPTPσ expression was modestly increased in ADPKD cell lysates
relative to the actin loading control (graph not shown), while RPTPδ
expression was uniform in normal and ADPKD cells. Both RPTPσ and
RPTPδ were coimmunoprecipitated with E-cadherin and full-length
polycystin-1 (460 kDa) from normal and ADPKD cell lysates, andwere
not statistically different (Fig. 5A, graph). Smaller fragments of
polycystin-1 at 250 kDa and 150 kDa correspond to known cleavage
products [74,78]. All RPTPs and their subunits were found speciﬁcally
co-precipitated and enriched with E-cadherin as compared to isotype
control immunoprecipitations (Fig. 5B). The RPTP-E-cadherin inter-
action was also identiﬁed in immortalized cell lines using different
detergent conditions serving as an additional speciﬁcity control
(Fig. 5C). Actin was not recovered in the immunoprecipitated
fractions indicating that the detected complexes were not due to a
co-precipitating cytoskeletal network. Based on the composite data,
the RPTPs are identiﬁed as complexed to E-cadherin, as well as the
polycystins.3.6. RPTPγ, but not RPTPσ, dephosphorylates polycystin-1 at Y4237
The Y4237 residue has been identiﬁed to be speciﬁcally phos-
phorylated in C-terminal tail constructs of polycystin-1 [13]. To
determine if polycystin-1 can serve as a substrate of the RPTP
phosphatases, Y4237 of recombinant polycystin-1 C-terminus was
ﬁrst phosphorylated by c-Src prior to incubation with the catalytic D1
domains of RPTPσ and RPTPγ in a dephosphorylation assay. The
phosphatase activity of each RPTP domain was determined using p-
nitrophenyl phosphate (pNPP) as a substrate. Measuring the loss of
32P-label from the polycystin-1 C-terminus, demonstrated that with
equal unit activity, RPTPγ D1 was able to speciﬁcally dephosphorylate
Y4237 of polycystin-1, while LAR D1, RPTPσ D1, and a substrate-
trapping inactive mutant of RPTPγ D1 were essentially inactive
(Fig. 6A). An equimolar amount of the regulatory RPTPσ D2 was used
as a negative control. Similar results were obtained using a kinetic
assay measuring phosphate release, again showing that the RPTPγ
D1 domain rapidly dephosphorylated the polycystin-1 C-terminus
when compared to RPTPσ and LAR D1 domains (Fig. 6B). These data
identify RPTPγ as a potential physiological regulator of polycystin-1
function.Fig. 4. RPTPσ and RPTPδ localisation in renal epithelial cells. (A) Stably transfected IMCD cel
labeled with DAPI (blue). The expressed RPTPσ isoform is amajor isolated from a kidney cDN
(17G7.2 mAb) and polycystin-1 (PKD domain 1, Dom1 pAb) at the basolateral membrane
cadherin at the lateral membrane in A431 cells. (D-E) Confocal immunoﬂuorescence images
(KTRPTPσ) and E-cadherin (Transduction Laboratories). (F–G) Confocal immunoﬂuorescen
cadherin. Panels D and F: cells were grown on glass coverslips. Panels E and G: cells were g
normal (67 F05) and ADPKD (51 M06) primary kidney cells labelled with antibodies direct
immunoﬂuorescence images of subconﬂuent, spreading normal (57 M03) and ADPKD (46 F0
cadherin (Transduction Laboratories). N≥3 for all panels.3.7. Functional characterization of polycystin-1 Y4237
The location of Y4237 in the same C-terminal coiled-coil domain of
polycystin-1 that is responsible for interacting with polycystin-2 and
regulating its calcium channel activity suggests that this residue may
be pivotal for regulating protein-protein interactions. Y4237 together
with nearby residues Y4127 and Y4147 may also regulate signaling
activity through reversible phosphorylation. In a yeast-2-hybrid
interaction assay, the Y4237F mutation of polycystin-1 did not affect
the interaction of the C-terminus of polycystin-1 with the C-terminus
of polycystin-2 (Data not shown). By immunoﬂuorescence, the wild-
type and Y4237F mutant forms of a membrane targeted CD44-
polycystin-1 C-terminus chimera (CD44-CTD) both localised to the
basolateral membrane of MDCK cells (Fig. 6C).
The signaling functions of Y4127, Y4147 and Y4237 were assessed
individually and in combination using an AP-1 reporter assay. A
myristylated polycystin-1 C-terminal construct, pMyr-PKD1, was
used to assay the modulation of AP-1 signaling in HEK293 cells.
Expression of the myristylated polycystin-1 C-terminus produced a
highly reproducible activation of AP-1 (Fig. 6D). Mutation of the
conserved tyrosine residues, Y4127 (in the G-protein activation
domain of polycystin-1) and Y4237 demonstrated that both tyrosine
residues were essential for AP-1 activation producing a response
equivalent to a 4147X truncating mutation lacking the coiled-coil
domain (Fig. 6D). Equal expression of all non-truncating constructs
was conﬁrmed using western blotting and densitometry (Fig. 6E).4. Discussion
In this study we identify RPTPσ, RPTPδ and RPTPγ as novel
interacting partners of polycystins (Fig. 7). Direct interactions
between RPTPγ and both polycystin-1 and polycystin-2 are demon-
strated and the ﬁrst Ig repeat of RPTPσ (but not LAR) interacts with
the ﬁrst PKD1 domain of polycystin-1. RPTPδ is most likely complexed
with the polycystins indirectly through interactions between RPTPσ
and RPTPδ. The RPTPs are components of a known polycystin/E-
cadherin protein complex and are co-localised at the lateral
membranes of renal epithelia. All of the RPTPs also co-localise with
polycystin-1 in cilia. The levels of RPTPs detected at the plasma
membrane of renal epithelial cells were low, while a larger pool was
present on intracellular membranes. Strong plasma membrane
staining and limited intracellular staining was observed in A431
cells. This suggests that plasma membrane expression may be
dependent on cell type and in ﬂux with an intracellular pool. In
ADPKD cells, the polycystin/RPTP complexes were altered with RPTPγ
being absent and the proteins exhibited different localisations. Finally,
functional studies show that polycystin-1 regulated AP-1 activity
required RPTPγ. Together the data suggest that several members of
the LAR subfamily (type IIA) of RPTPs are key regulators of the
polycystins in multiple cellular locations.
The associations of the RPTPs with the polycystins in cilia and at
cell–cell adherens junctions are in keeping with their known
functions in the kidney and other systems. RPTPσ and RPTPδ have
adhesionmolecule-like Ig repeats and alongwith RPTPδ havemultiple
ﬁbronectin-like domains [57,79]. RPTPσ regulates diverse cellularls expressed RPTPσ::GFP construct (green) at the basolateral plasma membrane. Nuclei
A library, lacking FNIII domains 4–7. (B) Confocal immunoﬂuorescence images of RPTPσ
in IMCD cells. (C) Confocal immunoﬂuorescence image of RPTPσ (17G7.2) and pan-
of conﬂuent RCTEC and PKD9–12 cells labelled with antibodies directed against RPTPσ
ce images of conﬂuent RCTEC and PKD9–12 cells labelled for RPTPδ (KTPTPδ) and E-
rown on 0.4 μm ﬁlter supports. (H) Confocal immunoﬂuorescence images of conﬂuent
ed against RPTPσ (KTRPTPσ) and E-cadherin (Transduction Laboratories). (I) Confocal
4) primary kidney cells labelled with antibodies directed against RPTPδ (KTPTPδ) and E-
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Fig. 5. (A) RPTPs co-immunoprecipitate with E-cadherin and polycystin-1 in normal kidney (NK) and ADPKD primary cells. The expression of RPTPσ and RPTPδwas conﬁrmed in normal and
ADPKD cell lysates. E-cadherin was immunoprecipitated with a monoclonal antibody from cell lysates and immunoblot analysis was performed to conﬁrm the presence of E-cadherin and
polycystin-1 in the immunoprecipitates. Immunoblot analysis demonstrated the presence of RPTPσ and RPTPδ in the complex. Proteins were detected with the following antibodies: pan-
cadherin used to detect E-cadherin on blots (Sigma), polycystin-1 (NM005), RPTPσ (KTPTPσ) and RPTPδ (KTPTPδ) and actin (MP Biomedical) as a loading control. Representative results from
one of four independent trials. Three normal adult kidney primary cell lines (67F05, 59M04, 57M03) and three ADPKD kidney primary cell lines (51M06, 46M06, 46F04) were used for these
experiments. Arrowheads denote lower molecular weight bands seen on PC1 blot represent commonly observed cleavage products of 250 and 150 kDa. Graph shows densitometric
quantiﬁcation of two independent trials RPTP IP/E-cadherin IP:RPTP lysate/actin±SEM. (B) RCTEC cell lysates were prepared and immunoprecipitated (IP) for E-cadherin (pAb) or using a
normal rabbit IgG control antibody. Individual blotswere probed for polycystin-1 (anti-LRR), E-cadherin (mAb), RPTPσ (pAbC19), RPTPδ (KPTPδ) and RPTPγ (pAbC18).Molecularweights are
as indicated. Arrows indicate the co-precipitated proteins. Asterisks denote non-speciﬁc bands. Graph shows enrichment calculated as fraction of protein immunoprecipitatedwith E-cadherin
antibody relative to the fractionofproteinprecipitatedwith control IgG.N=2. (C)E-cadherin-RPTPcomplexes formstable complexes that are resistant todissociation in twodifferentnon-ionic
detergents. Immortalized normal human kidney (RCTEC) or ADPKD cells (PKD9-12) were grown to conﬂuence and lysed in Triton X-100 (TX) or n-octylglucoside (OG) containing buffer. Cell
lysates (CL) and samples immunoprecipitated (IP) for E-cadherin usingmonoclonal (mEcad) or polyclonal (pEcad) were resolved via SDS-PAGE and immunoblotted with antibodies directed
against actin, E-cadherin (arrowhead denotes Ig bands), pan-cadherin, RPTPσ and RPTPδ as indicated with respective molecular weights as indicated. N=4.
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channel regulation and adhesion complex formation [80–84]. RPTPγ
inactivation in mice gives rise to only minor behavioral disturbance,suggesting functional redundancy, and has recently been shown to
play a role in neural adhesion [85,86]. Functional redundancy among
the RPTPs is further evidenced by the necessity for double knockout
Fig. 6. Y4237 phosphorylated polycystin-1C-terminus is dephosphorylated by RPTPγD1 and regulates AP-1 signaling. (A). Equal amounts of c-Src 32P tyrosine phosphorylated
polycystin-1 C-terminus were incubated with 10 units of each individual phosphatase domain and dephosphorylation determined by autoradiography. Upper bands (60 kDa)
represent autophosphorylated c-Src and lower bands CPC-1 (30 kDa). (B). Time dependent dephosphorylation of 32P-phospho-tyrosine in the polycystin-1 C-terminus by RPTPγ D1,
LAR D1 or RPTPσ D1. (C). Confocal immunoﬂuorescence images of MDCK cells labelled with antibodies directed against CD44 (E1/2) (labels polycystin-1 C-terminal fusion proteins:
CD44-CTD-WT and CD44-CTD-Y4237F mutation) and pan-cadherin. (D) The C-terminus of polycystin-1 activates AP-1 in a luciferase reporter assay. HEK293 cells were co-
transfected with individual pMyr-EGFP-CTD and 5xjun:ATF ﬁreﬂy luciferase reporter constructs. Cell lysates were collected 48 h after transfection, and luciferase activities measured.
Comparisons were made with pMyr-EGFP-CTD4147X co-transfected with the 5x-jun reporter construct and a negative (neg) control transfected with the 5x-jun reported construct
only. Experiments were carried out in triplicate and the mean and standard deviation of relative luminescence plotted. A two-tailed paired Student t-test was performed for the
luciferase activities of each construct compared with the wild type and * indicates statistical signiﬁcance pb0.05 for each mutant when compared to wild-type activity. (E). Left
panel: Immunoblot probed with anti-GFP (Ab6556; AbCam) demonstrates equal protein expression of all constructs (arrows) used in AP-1 assay. A non-speciﬁc band detected by
the anti-GFP antibody is seen in all lanes (*). Right panel: Experiments were carried out in triplicate, densitometry was performed to measure the levels of expression of each
chimeric protein (wild type, Y4127F, Y4237F and Y4127F/Y4237F pMyr-EGFP-CTD), and the mean relative expression and standard deviation plotted. A two-tailed paired Student t-
test was performed for each construct compared with the wild type and * indicates statistical signiﬁcance pb0.05. N=3.
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hypothesis, previous observations identiﬁed an additional RPTP
isoform (RPTPα) as a binding partner of RPTPσ D1 [58], which we
also observed in our yeast two-hybrid screens (not shown). Although
RPTPσ, RPTPδ and RPTPγ are all expressed in the kidney (reviewed in
[55]), renal cyst formation has not been described in single RPTPσ,
RPTPδ or RPTPγ knock-out models. However, RPTPδ has been
identiﬁed as a candidate modiﬁer of polycystic kidney disease in the
cpkmouse suggesting that different alleles of RPTPsmay act as genetic
modiﬁers of polycystic kidney disease severity [88].While it is evident
that RPTPs are likely important in kidney cell differentiation, signaling
and adhesion, a more complete understanding of the regulatory roles
of RPTPs in kidney (paralleling the in depth studies that have been
done for brain development) will depend on long-term survival
studies and double knock-out animals.
Polycystin-1 localises to basolateral and ciliary membranes and is
implicated in the regulation of processes such as cell migration,
adhesion, proliferation and ciliary signaling, much like the RPTPs. The
formation of a polycystin-1/RPTP/ E-cadherin complex suggests that the
RPTPs play a role in cell–cell adhesion and identiﬁes the tyrosine
phosphatases shown previously to co-precipitate with a ﬂotillin-2/
polycystin-1/E-cadherin complex [34]. RPTPσ and RPTPδ were also
found to coimmunoprecipitate with N-cadherin (data not shown).
These data agree with the known localisation of RPTPσ to adhesion
complexes where it can functionally associate with N-cadherin/β-
catenin and dephosphorylateβ-catenin and other desmosomal catenins
such as plakoglobin (γ-catenin) [32,61,89]. Further support for a role of
regulated tyrosine phosphorylation in adhesion complex formation
comes from the observation that phosphatase inhibitors result in
tyrosine phosphorylation of adherens junction proteins and deteriora-
tion of junctional structures [33]. Inhibition of tyrosine phosphorylation
also disrupts polycystin-1–FAK interactions [12]. In ADPKD epithelia
polycystin-1 has been shown to be hyperphosphorylated and suggested
to disrupt normal interactionswith E-cadherin [29]. Thus, the identiﬁed
polycystin/RPTP complex is likely important for the regulation of the
polycystins in multiple cellular locations.
Abnormalities in the structure and function of the renal primary
cilium have been identiﬁed in human and murine polycystic kidney
disease [90,91]. Deﬂection of the primary cilium results in increased
intracellular calcium, mediated by the polycystin channel complex
and ciliary signaling is abrogated in ADPKD cells [5,6,68]. However the
mechanisms underlying the activation and regulation of the poly-
cystin complex in adhesion complexes and the primary cilium are
poorly characterized. The importance of the ﬁrst PKD domain in
mechanotransduction has been demonstrated by the ability of
antibodies to this domain to block the cilia dependant ﬂow-induced
increase in intracellular calcium in renal epithelial cells [5,6,68]. This
domain also demonstrates unique force-induced biophysical proper-
ties further supporting its central role in mechanotransduction [18].
The “phage display” data identiﬁed a potential interaction between
the ﬁrst PKD domain of polycystin-1 and the ﬁrst Ig domain of RPTPσ.
The ﬁrst Ig domain of RPTPs has been shown to be a major ligand-
binding site recognizing heparan sulphate proteoglycans and chon-
droitin sulphate proteoglycans [92,93]. Therefore the identiﬁcation of
an RPTP-polycystin complex that localises to the primary cilium
suggests that mechanosensing and signaling properties are regulated
by tyrosine phosphorylation. RPTPδ has been identiﬁed in the mouse
photoreceptor sensory cilium proteome, which suggests a more
general role for RPTPs in cilia function [94]. RPTPα, the LAR-
interacting proteins Trio and liprin, and members of the cadherin
and catenin family were also identiﬁed in the same screen, suggesting
that both RPTP and cadherin functions are required for normal cilial
signaling.
RPTPζ, which has the same domain architecture as RPTPγ, has
been shown to interact extracellularly and intracellularly with
voltage-gated sodium channels where dephosphorylation leads toincreased channel activity [83,95]. Recently the extracellular carbonic
anhydrase domain of RPTPγ (residues 56–320) has also been shown
to interact with the Ig domains of members of the contactin family of
proteins involved in neural recognition [86]. Thus, the dual interaction
between both the extracellular and intracellular domains of the
polycystin-1 and RPTPσ and RPTPγ, is likely to enable both “outside-in
and inside-out” signaling (as described for the integrins) and convert
changes in adhesion to changes in cell behavior. A dual binding site
model predicts that an extracellular polycystin-1–RPTP interaction
serves as a sensor that regulates the function of polycystin-1 or
polycystin-2 by tyrosine phosphorylation. Therefore the intracellular
regions of the polycystins may regulate, or be substrates for, RPTPσ,
RPTPγ or RPTPδ. This model is supported by several observations.
Firstly, the C-terminus of polycystin-1 can interact with the RPTPγD2
and secondly, tyrosine phosphorylated polycystin-1 is a substrate of
RPTPγ D1 in vitro. RPTPγ D2 also interacts with RPTPσ D1 suggesting
that RPTPγ may be capable of regulating the dephosphorylation of E-
cadherin/β-catenin with RPTPσ. More intriguingly, RPTPγ D1 also
interacts with the C-terminus of polycystin-2 in our yeast two-hybrid
assay suggesting that tyrosine phosphorylation may regulate poly-
cystin-2 channel activity. Neural network predictions using Netphos
2.0, identiﬁed Y684 and Y836 as potential tyrosine phosphorylation
sites in polycystin-2. However, we were unable to detect endogenous
tyrosine phosphorylation of polycystin-2 in IMCD cells by immuno-
precipitation (unpublished data) although other TRP channels can be
regulated by this mechanism. Additional work will be required to
elucidate how dynamic changes in polycystin protein interactions
during cell differentiation are modulated by the RPTPs.
The signaling functions of polycystin-1 are mediated by the short
intracellular cytoplasmic tail, which contains serine and tyrosine
phosphorylation sites, a G-protein activation domain and a coiled-coil
protein interaction domain [13,96,97]. Studies have shown that the C-
terminal tail of polycystin-1 is able to regulate AP-1 signaling in a G-
protein dependant manner [8,98]. Aberrant AP-1 activation has also
been shown in ADPKD cells and tissues [7,44]. Using a Jun::ATF
luciferase reporter assay we show that two tyrosine residues in the C-
terminus of polycystin-1 (Y4127 in the G-protein activation domain
and Y4237 within the coiled-coil domain) are critical for polycystin-1
mediated AP-1 activity. As Y4237 does not alter the interaction with
polycystin-2 or the membrane localisation of polycystin-1, it suggests
that it is crucial for the direct interaction with components regulating
the AP-1 signaling pathway.5. Conclusions
The cumulative data suggest that RPTPs can regulate the mechan-
osensitive, adhesive and signaling properties of the polycystin complex.
We postulate that in the renal primary cilium an interaction between
polycystin-1 with the extracellular region of RPTPσ forms the mechan-
osensing subunit of the complex that modulates activation of the
intracellular phosphatase domains with the subsequent dephosphory-
lation of Y4237 of polycystin-1 and regulation of AP-1 signaling. Other
subunits of the RPTP/polycystin-1 assembly in different localisations
and in associationwith distinct partners (e.g. adherens junctions and E-
cadherin/β-catenin)may also be regulated by this mechanism resulting
in altered compositionand stability of cell–cell and cell–matrix adhesion
complexes. Intriguingly, phosphatase activity is regulated byproteolytic
cleavage in response to calcium inﬂuxwith sheddingof the extracellular
domains of LAR and RPTPσ and redistribution of their intracellular
phosphatase domains away from sites of cell–cell contact [89].
Consequently, such a calcium dependent mechanism could simulta-
neously regulate polycystin-1 and phosphatase activation and enable
redistribution of polycystins from the lateral membranes to cilia as the
cells differentiate. Therefore, disruption of the polycystin–RPTP com-
plex, leading to altered phosphorylation of polycystin-1/adhesion
1237C.A. Boucher et al. / Biochimica et Biophysica Acta 1812 (2011) 1225–1238complex proteins and/or aberrant AP-1 activation may be critical in
establishing a renal cystic phenotype.
Supplementary materials related to this article can be foundonline
at doi:10.1016/j.bbadis.2010.11.006.
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